These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20171408)

  • 21. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis.
    Iida O; Soga Y; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M; Muramatsu T; Inoue N; Nanto S; Uematsu M
    J Endovasc Ther; 2011 Dec; 18(6):753-61. PubMed ID: 22149222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infrapopliteal run-off and the outcome of femoropopliteal percutaneous transluminal angioplasty.
    Salapura V; Blinc A; Kozak M; Jezovnik MK; Pohar Perme M; Berden P; Kuhelj D; Kljucevsek T; Popovic P; Stankovic M; Vrtovec M; Surlan M
    Vasa; 2010 May; 39(2):159-68. PubMed ID: 20464672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty.
    Minar E; Ahmadi A; Koppensteiner R; Maca T; Stümpflen A; Ugurluoglu A; Ehringer H
    Circulation; 1995 Apr; 91(8):2167-73. PubMed ID: 7697845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Comparative Cost-Effectiveness Analysis of Percutaneous Transluminal Angioplasty With Optional Stenting and Femoropopliteal Bypass Surgery for Medium-Length TASC II B and C Femoropopliteal Lesions.
    Vossen RJ; Philipszoon PC; Vahl AC; Montauban van Swijndregt AD; Leijdekkers VJ; Balm R
    J Endovasc Ther; 2019 Apr; 26(2):172-180. PubMed ID: 30898070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender-related long-term outcome of primary femoropopliteal stent placement for peripheral artery disease.
    Stavroulakis K; Donas KP; Torsello G; Osada N; Schönefeld E
    J Endovasc Ther; 2015 Feb; 22(1):31-7. PubMed ID: 25775677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
    Kamioka N; Soga Y; Kuramitsu S; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamaoka T; Suematsu N; Shintani Y; Miyashita Y; Takahashi H; Tsuchiya T; Shinozaki N; Okazaki S; Ando K
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):790-797. PubMed ID: 28722294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions: 1-year follow-up.
    Schillinger M; Mlekusch W; Haumer M; Sabeti S; Ahmadi R; Minar E
    J Endovasc Ther; 2003 Apr; 10(2):288-97. PubMed ID: 12877612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraarterial (192)Ir high-dose-rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna-2-trial radiotherapy parameters and risk factors analysis.
    Pokrajac B; Pötter R; Maca T; Fellner C; Mittlböck M; Ahmadi R; Seitz W; Minar E
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):923-31. PubMed ID: 11072147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
    Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
    J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis.
    Giannopoulos S; Lyden SP; Bisdas T; Micari A; Parikh SA; Jaff MR; Schneider PA; Armstrong EJ
    Cardiovasc Revasc Med; 2021 Jan; 22():52-65. PubMed ID: 32563709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions.
    Iida O; Nanto S; Uematsu M; Morozumi T; Kitakaze M; Nagata S
    J Vasc Surg; 2008 Jul; 48(1):144-9. PubMed ID: 18482817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Yamada S; Kasuga H; Ichimiya S; Kanashiro M; Mitsuhashi H; Maruyama S; Matsuo S; Naruse K; Matsubara T; Murohara T
    Clin Ther; 2007 Jan; 29(1):110-22. PubMed ID: 17379051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience.
    Kudo T; Chandra FA; Ahn SS
    J Vasc Surg; 2005 Mar; 41(3):423-35; discussion 435. PubMed ID: 15838475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTA and Stenting of Femoropopliteal Trunk With Cordis Smartflex Stent System: A Single-Center Experience.
    Garriboli L; Miccoli T; Pruner G; Jannello AM
    Vasc Endovascular Surg; 2020 Jan; 54(1):17-24. PubMed ID: 31526118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):664-672. PubMed ID: 30747489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.